 Estradiol
"Estradiol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Generally refers to the 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the PLACENTA. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (RECEPTORS, ESTROGEN) and exhibits little estrogenic activity in estrogen-responsive tissues. Various isomers can be synthesized.
| Descriptor ID |
D004958
|
| MeSH Number(s) |
D04.808.365.415.248 D06.472.334.851.437.500
|
| Concept/Terms |
Estradiol- Estradiol
- 17 beta-Oestradiol
- 17 beta Oestradiol
- Estradiol-17beta
- Estradiol 17beta
- Oestradiol
- 17 beta-Estradiol
- 17 beta Estradiol
- Estradiol-17 beta
- Estradiol 17 beta
Ovocyclin- Ovocyclin
- Orion Brand of Estradiol
- Estradiol Orion Brand
Vivelle- Vivelle
- Novartis Pharmaceuticals Brand of Estradiol
|
Below are MeSH descriptors whose meaning is more general than "Estradiol".
Below are MeSH descriptors whose meaning is more specific than "Estradiol".
This graph shows the total number of publications written about "Estradiol" by people in this website by year, and whether "Estradiol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 3 | 4 | | 1981 | 2 | 2 | 4 | | 1982 | 0 | 3 | 3 | | 1983 | 2 | 2 | 4 | | 1984 | 3 | 2 | 5 | | 1985 | 1 | 4 | 5 | | 1986 | 2 | 2 | 4 | | 1987 | 0 | 2 | 2 | | 1988 | 3 | 3 | 6 | | 1989 | 1 | 2 | 3 | | 1990 | 0 | 6 | 6 | | 1991 | 0 | 2 | 2 | | 1992 | 4 | 0 | 4 | | 1993 | 2 | 5 | 7 | | 1994 | 1 | 2 | 3 | | 1995 | 2 | 2 | 4 | | 1996 | 2 | 6 | 8 | | 1997 | 3 | 2 | 5 | | 1998 | 4 | 2 | 6 | | 1999 | 2 | 2 | 4 | | 2000 | 4 | 6 | 10 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 3 | 5 | | 2003 | 8 | 1 | 9 | | 2004 | 0 | 3 | 3 | | 2005 | 3 | 2 | 5 | | 2006 | 3 | 2 | 5 | | 2007 | 4 | 6 | 10 | | 2008 | 2 | 3 | 5 | | 2009 | 6 | 4 | 10 | | 2010 | 1 | 2 | 3 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 4 | 6 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 2 | 2 | | 2016 | 0 | 2 | 2 | | 2017 | 2 | 1 | 3 | | 2018 | 3 | 2 | 5 | | 2019 | 2 | 2 | 4 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Estradiol" by people in Profiles.
-
Ali M, Chen HY, Chiang YF, Badary OA, Hsia SM, Al-Hendy A. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
-
Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
-
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Simon JA, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Dayspring T, Feinberg EC, Gillispie V, Hurtado S, Kim J, Liu R, Owens CD, Muneyyirci-Delale O, Wang A, Watts NB, Schlaff WD. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
-
Maximov PY, Abderrahman B, Hawsawi YM, Chen Y, Foulds CE, Jain A, Malovannaya A, Fan P, Curpan RF, Han R, Fanning SW, Broom BM, Quintana Rincon DM, Greenland JA, Greene GL, Jordan VC. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
-
Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
-
Weiser M, Levi L, Zamora D, Biegon A, SanGiovanni JP, Davidson M, Burshtein S, Gonen I, Radu P, Slobozean Pavalache K, Nastas I, Hemi R, Ryan T, Davis JM. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
-
Adeleye AJ, Cedars MI, Smith J, Mok-Lin E. Ovarian stimulation for fertility preservation or family building in a cohort of transgender men. J Assist Reprod Genet. 2019 Oct; 36(10):2155-2161.
-
Mitchell CM, Guthrie KA, Larson J, Diem S, LaCroix AZ, Caan B, Shifren JL, Woods NF, Heiman JR, Lindau ST, Reed SD. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women. Menopause. 2019 08; 26(8):816-822.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|